Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of HD CD19 CAR-T in relapsed or refractory B-cell acute lymphoblastic leukemia
CTR20232554Phase 2Active
- Sponsor
- Huadao Biomedical
- Start
- Apr 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of HD CD19 CAR-T in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Huadao Biomedical. Started Apr 2024; status: active.
02
Drugs
HD CD19 CAR-T
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on CTR20232554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232554.